Destiny Pharma plc
("Destiny Pharma" or the "Company")
Investor Presentation
Brighton, United Kingdom - 21st January 2021 - Destiny Pharma plc (AIM: DEST, "the Company") a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, is pleased to announce that Neil Clark and Shaun Claydon will deliver a live presentation introducing Destiny Pharma via the Investor Meet Company platform on 27th January 2021 at 11:00 am GMT.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9 am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet Destiny Pharma via:
https://www.investormeetcompany.com/destiny-pharma-plc/register-investor
Investors who already follow Destiny Pharma on the Investor Meet Company platform will automatically be invited.
Enquiries:
| Destiny Pharma plc | +44 (0) 1273 704 440 |
| Neil Clark (Chief Executive Officer)
| |
| finnCap Limited - Nominated Adviser and Joint Broker | +44 (0) 20 7220 0500 |
| Geoff Nash / Kate Bannatyne / Charlie Beeson (Corporate Finance)
| |
| WG Partners LLP - Joint Broker | +44 (0) 20 3705 9330 |
| Nigel Barnes / Claes Spång / Nigel Birks / Andrew Craig
| |
| Optimum Strategic Communications | +44 (0) 203 174 1789 |
| Mary Clark / Shabnam Bashir / Manel Mateus
| |
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which is in a Phase 2b clinical trial targeting the prevention of post-surgical Staphylococcal hospital including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.
For further information, please visit https://www.destinypharma.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
